Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-17,340
Closed -$270K 7
2016
Q4
$270K Sell
17,340
-49,395
-74% -$758K 5.64% 8
2016
Q3
$990K Sell
66,735
-211,875
-76% -$2.99M 5.71% 4
2016
Q2
$3.56M Sell
278,610
-70,640
-20% -$984K 0.15% 204
2016
Q1
$4.99M Sell
349,250
-29,785
-8% -$405K 0.19% 177
2015
Q4
$5.32M Sell
379,035
-97,990
-21% -$1.43M 0.16% 181
2015
Q3
$6.2M Buy
477,025
+34,015
+8% +$472K 0.28% 118
2015
Q2
$6.6M Buy
443,010
+177,960
+67% +$2.76M 0.13% 209
2015
Q1
$3.73M Buy
265,050
+4,550
+2% +$59.5K 0.07% 233
2014
Q4
$3.26M Buy
260,500
+45,000
+21% +$589K 0.03% 336
2014
Q3
$2.97M Sell
215,500
-5,500
-2% -$84.4K 0.02% 453
2014
Q2
$3.67M Buy
+221,000
New +$3.37M 0.03% 407

Other funds holding IX

Euclid Advisors's IX Position: Q1 2017 in Review

Euclid Advisors sold out of ORIX (IX) in Q1 2017, closing a stake of 17,340 shares — an estimated $270K sold.

Euclid Advisors first reported a position in IX in Q2 2014 and held it in 11 quarters. The position peaked at $6.6M in Q2 2015. 129 funds tracked by Wall St. Rank hold IX as of Q1 2017.

  • Euclid Advisors reported no remaining ORIX position as of Q1 2017 after selling out during the quarter.
  • Euclid Advisors sold 17,340 ORIX shares in Q1 2017, an estimated $270K.
  • Euclid Advisors first reported a position in ORIX in Q2 2014 and held it in 11 quarters.
  • Euclid Advisors's ORIX position peaked at $6.6M in Q2 2015.
  • 129 funds tracked by Wall St. Rank held ORIX as of Q1 2017.

Based on Euclid Advisors's 13F filing for Q1 2017.